Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesenchymal stem cells for posterolateral spinal fusion in degenerative spine disease
2010-024665-52Phase 2Terminated
- Sponsor
- Bioinova
- Start
- Mar 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human autologous mesenchymal stem cells in degenerative spinal conditions and degenerative disc disease (DDD), sponsored by Bioinova. Primary endpoints: Local spinal fusion complications and Treatment-emergent adverse events. Started Mar 2013; status: terminated.
02
Drugs
human autologous mesenchymal stem cells
03
Conditions
degenerative spinal conditionsdegenerative disc disease (DDD)
Beyond the preview
Go deeper on 2010-024665-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024665-52.